Inhaled Steroids for Kids' Asthma: Are Higher Doses Always Better?
"Debunking the Myth: Research shows increasing inhaled steroid doses during asthma flare-ups doesn't necessarily reduce the need for systemic steroids in children."
Asthma, a chronic respiratory condition, affects a significant number of children, impacting their quality of life and placing a burden on families and healthcare systems. Effective management of asthma is crucial, and inhaled corticosteroids (ICS) play a vital role in controlling symptoms and preventing flare-ups.
When children experience asthma flare-ups, parents and healthcare providers often consider increasing the dose of ICS to quickly alleviate symptoms and prevent the need for oral steroids, which can have undesirable side effects. But is this approach always the most effective?
Recent research, including a Cochrane review analyzing data from multiple pediatric studies, challenges the assumption that higher doses of ICS during flare-ups are more beneficial. This article explores the findings of this review and what they mean for managing asthma in children.
Why Dose Decisions Matter
For children with asthma, inhaled steroid treatment is generally individualized rather than determined by dose alone. Clinicians weigh symptom control, exacerbation risk, treatment response, inhaler technique, and potential adverse effects. A higher dose may be appropriate in some situations, but it is not automatically better for every child.
Stepwise Treatment
Asthma care commonly follows a stepwise approach, adjusting treatment according to the level of control and the patient's response. Inhaled corticosteroids are used to manage airway inflammation, with dose changes made when control is inadequate or treatment can be reduced safely. This approach remains limited by differences in adherence, inhaler technique, disease severity, and individual response.
Fifty Years of Inhaled Corticosteroids
Inhaled corticosteroids are described as the foundation or cornerstone of asthma therapy, and 2026 marks roughly 50 years since their introduction. The history of inhaled asthma treatment is also linked to the first pressurised metered-dose inhaler, introduced in 1956. Before inhaled corticosteroids, bronchodilators such as beta2-agonists and anticholinergic agents were the main asthma therapies; the field is therefore often described as having a distinct period before and after inhaled corticosteroids.
The Great Inhaled Steroid Debate: What the Research Reveals
A comprehensive Cochrane review examined the effectiveness of increasing ICS doses versus maintaining stable doses in children experiencing asthma flare-ups. The analysis focused on whether increasing ICS reduced the need for systemic corticosteroids (oral steroids) to control the flare-up.
- No Significant Difference: Children who increased their inhaled steroid dose were just as likely to require systemic corticosteroids as those who stuck to their regular maintenance dose (Odds Ratio 0.93, 95% CI 0.61-1.41).
- Limited Data on Other Outcomes: The review found insufficient evidence to determine if increased ICS doses affected rates of unscheduled doctor visits, emergency room visits, or hospital admissions.
- Study Details: The included studies compared increased ICS doses to maintenance doses at the onset of asthma flare-ups, within the context of a patient-initiated asthma action plan. The primary outcome was the subsequent need for systemic corticosteroids.
Evidence Continues to Evolve
Recent research continues to examine how inhaled corticosteroids should be selected, combined, and adjusted for different asthma patterns. Reviews may clarify which patients benefit from particular regimens, but evidence does not support assuming that escalation is uniformly beneficial. Treatment decisions therefore remain dependent on the clinical question being studied and the patient's response.
Why More Is Not Always Better
Increasing an inhaled steroid dose may not solve poor asthma control when the underlying problem is inconsistent use, incorrect inhaler technique, or an inadequate treatment plan. Higher exposure can also raise concern about adverse effects, so escalation requires a balance between expected benefit and potential harm. Persistent symptoms should prompt reassessment rather than an automatic assumption that the dose should keep increasing.
Comparing Inhaled Options
A 2024 systematic review and network meta-analysis examined whether inhaled corticosteroids combined with short-acting beta agonists or formoterol were more effective than short-acting beta agonists alone for reducing exacerbations and improving asthma control. The available options include inhaled corticosteroids such as Fluticasone, Qvar, Pulmicort, Alvesco, and Asmanex. Inhaled corticosteroid/long-acting beta-agonist therapy remains a mainstay of asthma management, but real-world comparative evidence across different formulations is still described as limited.
Rethinking Asthma Flare-Up Management: A More Holistic Approach
The research highlights the need for a more nuanced approach to managing asthma flare-ups in children. Instead of solely relying on increased ICS doses, a comprehensive strategy should be implemented, guided by a healthcare professional.
Balancing Control and Exposure
The evidence summarized here does not establish that high-dose inhaled corticosteroids should routinely replace lower-dose strategies. A systematic review reported that high doses reduced hospital-admission risk for patients with acute asthma presenting to an emergency department, but concluded that the evidence was insufficient to change clinical practice. For moderate-to-severe asthma, inhaled corticosteroid/long-acting beta2-agonist medicines are described as the current standard of maintenance care, while ongoing research is examining maintenance doses and adverse effects.
More Individualized Care
Future asthma care is likely to focus on matching treatment intensity to each patient's symptoms, risk, response, and tolerance. Research may help clarify when to step up, when to step down, and how to choose among available inhaled therapies. Until that evidence is more complete, careful monitoring and reassessment remain important.
Systemic Effects and Long-Term Use
Inhaled corticosteroids are frequently prescribed for inflammatory airway diseases including asthma and chronic obstructive pulmonary disease. They are identified as step 2 on the asthma management ladder, and their prescribing clinicians are urged to review potential systemic complications regularly. Research has also examined the efficacy of combining inhaled corticosteroids with long-acting beta-agonists, showing that treatment choices involve both benefits and longer-term safety considerations.
What Happens in Everyday Care
Real-world evidence links low inhaled corticosteroid adherence with increased asthma burden, although the relationship may be bidirectional. A 2024 real-world study reported additional support for as-needed inhaled corticosteroid/formoterol as a preferred treatment for people with mild asthma, while as-needed short-acting beta-agonist use was associated with falling lung function and more severe exacerbations. Another study assessed outcomes after patients escalated from medium-dose inhaled corticosteroids to either high-dose inhaled corticosteroids or biologics, highlighting that escalation decisions can involve more than simply increasing the steroid dose.
This strategy should include regular monitoring of symptoms, trigger identification and avoidance, optimization of baseline ICS therapy, and a well-defined asthma action plan that outlines when and how to use rescue medications like short-acting beta-agonists. It also suggests that a stepwise approach should be considered, where other therapies like oral steroids are introduced in certain cases.
While increased ICS might be appropriate in some cases, it shouldn't be the default response for every flare-up. Parents and caregivers should work closely with their child's doctor to develop a personalized asthma management plan that addresses the individual needs and triggers of the child, and ensures the judicious use of oral corticosteroids to prevent any adverse effects.